Red Light Holland is vertically integrated from spore to truffle in the Netherlands and sells their magic to customers in stores, online as well as wholesale.
DRUG PROGRAMS TARGET: ADHD, Existential crisis/Palliative care, Neuroinflammation, Alzheimer’s markers Depression, PTSD, Anxiety, Substance Use Disorders (Alcohol, Stimulants, Opioids).
PARTNERSHIP NETWORK DEVELOPMENT PROGRAM: This program generates revenue through licensing partnerships with the company’s chemicals.
ACADEMIC AND PHILANTHROPIC LOW-COST PARTNERSHIPS: This program provides low- or no-cost study drugs to academic researchers and retain safety data for in-house programs.
FACILITIES: 3,500 sq ft of GMP-compliant manufacturing, research and development on the British Columbia Institute of Technology’s campus.
SUBSTANCE FOCUS: Psilocybin.
CLINICAL TRIALS: Yes.
OWNERSHIP:
100% – Red Light Farms in Horst, The Netherlands produces truffles for the iMicrodose and Maka brands as well as white-labels
100% – SR Wholesale distributes truffles and other products to 200+ stores s in The Netherlands with the ability to distribute non-truffle products to another 1000 stores across the EU.
100% – RadixMotion
Happy Caps Mushroom Farm is a Canadian retailer and manufacturer of premium in-door home mushroom growing kits with specimens like shiitake, lion’s mane and oyster mushrooms.
MiniChamp is a specialist in the field of home cultivation kits in mushrooms and the idea behind the company is that everyone can grow their own mushrooms at home. The company is based in the Netherlands and ships worldwide.
80% – PharmaDrug is a German medical cannabis distributor, with a Schedule I European Union narcotics license allowing for the importation and distribution of medical cannabis to pharmacies in Germany and throughout the EU.
100% – Super Smart, an early-stage retail company focused on consolidating the fragmented Dutch smartshop market.
51% – Acadian Exotic Mushrooms
40% – Magdalena Biosciences
Filament Health formed Magdalena Biosciences claiming 40%, together with Jaguar Health which owns the other 40% and One Small Planet owns the 20% left. Magdalena is US-based and was formed in 2023 to develop novel, natural prescription medicines derived from plants for mental health conditions including ADHD, depression and social anxiety.
FarmCare Health is an innovative initiative launched by Red Light Holland that seeks to revolutionize the healthcare industry by integrating nutrition directly into patient care. With a mission to address the root causes of health issues, the program advocates for “farm-fresh food prescriptions,” utilizing the company’s own sustainably grown mushrooms and home grow kits to combat food insecurity and improve overall health outcomes. Led by Senior Advisor Tony Clement, the former Canadian Health Minister and Industry Minister, the initiative envisions a future where access to nutritious, farm-fresh produce is treated as a fundamental right and as essential as any other clinical healthcare intervention.
The program is currently focused on developing pilot projects that educate both healthcare providers and patients on the transformative power of a food-as-medicine approach. By bridging the gap between agriculture and public health, FarmCare Health aims to create resilient communities and foster a sustainable supply chain for healthy food across Canada and beyond. While initially launched with a modest capital commitment, Red Light Holland is prepared to scale its investment significantly as the initiative gains traction, signaling a long-term strategic commitment to holistic wellness and the company’s broader mission to enhance the quality of life for individuals globally.
FACILITIES:
3,000 sq ft custom-built, indoor growing, production and distribution facility in Horst, the Netherlands for Red Light Farms.
2 mushroom production facilities with 65,000 sq ft for mushroom production on 100 acres in Peterborough, Canada for AEM Farm.
AEM Farms Ontario, an 85,000 sq ft state-of-the-art vertical mushroom farm and composting facility in Peterborough, Ontario.
22,000 sq ft facility on approximately 4 acres of land in Eel River Crossing, New Brunswick. (AEM)
NEWS & PARTNERSHIPS:
2020
The company announced a partnership with Khloe Terae as its Clothing Brand Ambassador.
The company engaged RadixMotion to design and develop a digital care program for people exploring microdosing. The program will accompany customers from the first time they encounter iMicrodose products in Smartshops via the iMicrodose Media Information Centre (“iMIC”) with an educational interactive augmented reality app. The core of the digital care program is a privacy first iMicrodose Journal, a web app where people can anonymously document their microdosing and receive data driven analytics that will help them make informed choices around their usage. The app will use Radix Motion’s expertise in biometric human pose data to give people feedback on whether microdosing has measurable effects on reducing their physiological tension or influences other features of their body posture.
The company reached an agreement with Smartshop Oss to build and set up an iMicrodose Media Information Centre and that their iMicrodose Packs powered by Red Light Holland are to be sold in Smartshop Oss.
The company started selling its iMicrodose Packs powered by Red Light Holland to 3 House of Smart locations, in Rotterdam, Eindhoven and Den Bosch, Netherlands.
The company secured a relationship with Jinfiniti Precision Medicine to in order to explore the potential roles that psilocybin and truffles can play for age-related and psychiatric disorders.
The company announced that their iMicrodose Packs powered by Red Light Holland to be sold in PharmaDrug’s store in Tiel which will also build and set up an iMicrodose Media Information Centre at the location.
The company launched sales of its iMicrodose Packs online in the Netherlands.
The company engaged Radixmotion to design and develop a virtual reality shopping experience module intended to explain the effects of microdosing of magic truffles on the human brain, as well as a virtual reality avatar that is centered around Red Light Holland’s brand and expected to be integrated into the Meu Platform.
The company announced that they will launch and host the High Times Psychedelic Podcast, a weekly podcast powered by Red Light Holland and featured by High Times.
The company announced that it has solidified its arrangement with McSmart for the launch of its Microdosing Packs through 3 Smart Shops operated by McSmart, 2 of them being Tatanka locations as well as sales made available online at Tatanka.
2021
The company acquired 51% of Acadian Exotic Mushrooms, a gourmet mushroom production facility co-owned by leading Canadian mushroom farming groups/individuals Holburne Mushroom Farm and Mike and Fernando Medeiros co-owners of Carleton Mushroom Farms. AEM will have the ability to produce, package and distribute a wide variety of fresh mushrooms, while offering an assortment of dried options and the potential to produce functional mushroom consumer packaged goods. Through the acquisition, the company entered into an offtake agreement with the vendors ensuring a minimum purchase price of 6 CAD per pound for all output from the facility for a 3-year period.
The company acquired Mera Life Sciences and its coveted psychedelic licenses in St. Vincent and the Grenadines. Mera was renamed to Scarlette Lillie Science and Innovation. Mera holds a Medicinal Industry Development License issued by the SVG Bureau of Standards, which permits the research, cultivation, production, development and extraction, import and export, clinical treatment facilities, and prescribed patient access in specifically licensed clinical treatment facilities. The license applies to Tumeric, Aloe Vera, Papaya, Arrowroot, Soursop, Coconut, Ginger, Moringa, Ayahuasca, Mushroom, Iboga, Sassafras, Peyote, Psilocybin, Ibogaine, DMT, Mescaline, Ketamine, MDMA, LSD, 5-MeO-DMT.
Filament Health exported the first GMP-compliant natural psilocybin from Filament’s Vancouver facility to the University of California San Francisco’s Translational Psychedelic Research Program in connection with an anticipated phase 1 FDA trial and ongoing clinical trial partnership.
Filament Health announced FDA-authorization for the first direct administration of psilocin in a clinical trial, using naturally sourced psychedelic substances. The phase 1 trial is led by the Translational Psychedelic Research Program at the University of California in San Francisco which will administer Filament’s three proprietary botanical drug candidates.
Filament Health became the first public company to be issued a patent by the Canadian Intellectual Property Office for the extraction and standardization of natural psilocybin and associated psychoactive compounds. The patent describes essential technology for transforming variable psychedelic raw materials into pharmaceutical-grade standardized extracts.
Filament Health entered into a co-development and exclusive licensing agreement with EntheoTech Bioscience where Filament will exclusively license its botanical psilocybin drug candidate, PEX010, to EntheoTech for 2 upcoming clinical trials addressing opioid use for chronic pain and depression. Separately, Filament will co-develop psychedelic drug candidates derived from mushrooms grown from EntheoTech’s proprietary spore library.
Filament Health was granted an amendment to its existing Health Canada Dealer’s License, allowing the possession, production, research supply, export, import, and delivery for all remaining controlled natural psychedelic substances, including DMT, mescaline and others.
Russell Peters will be filmed when he is having his first psychedelic journey with Red Light Holland’s natural psilocybin truffles and therapist and expert psychedelic guide Jeff Hamburg. Peter will give a special performance in front of a live audience which will be live streamed on Red Light Holland social media accounts after he has completed his journey and integration session.
The company completed Canada’s largest legal sale and import of psilocybe truffles into Canada, amounting to 1,5 KG of truffles grown in Horst, Netherlands and given to its laboratory partner, CCrest Laboratories.
The company announced the availability of iMicrodose Packs powered by Red Light Holland in 6 more locations.
The company acquired Radix Motion.
The company acquired 80% of Happy Caps Mushroom Farm which specializes in grow-at-home mushroom kits and sells fresh mushrooms for the wholesale market. The vendors granted the company an option to acquire all the remaining shares in Happy Caps, exercisable at any time following a period of 2 years from closing.
The company launched its virtual telecounseling membership program on the company’s iMicrodose Digital Care app in the Netherlands. The telecounseling membership program will be seamlessly integrated into the privacy first iMicro Digital Care web app creating a new frontier for virtual psychedelic platforms. Online support will be offered to adults exploring microdosing with iMicrodose packs powered by Red Light Holland in the Netherlands. Members will be able to approve and share their iMicro Digital Care app data and connect with Red Light Holland’s certified therapist and microdosing expert, Jeff Hamburg, who will provide live virtual telecounseling.
Anvisa, Brazil’s National Health Regulatory Agency granted authorization for the company’s iMicrodose packs.
The company’s VR Experience, Wisdom was accepted to Steam for sale at a price point of 4.99 USD. Wisdom is narrated by Russell Peters and explains the effects of psychedelics on the brain within the predictive coding neuroscience framework and takes users into a unique VR immersive experience providing stunning visuals and copious amounts of education and information promoting responsible use.
The company acquired SR Wholesale, one of the Netherlands’ premiere distributors for quality psychedelic truffles. SR Wholesale also distributes popular CBD products, cannabis seeds, smart shop items, and headshop products, among others. SR Wholesale has established a distribution network of over 400 companies that sell their products across Europe, including working with sub-distributors which provide products to over 1,000 shops in countries like the Netherlands, Germany, Spain, Czech, Greece, UK, France, and Portugal. This gives the company an opportunity to white label to help with brand growth, exposure and expansion.
2022
The company announced that Happy Caps Mushroom Farm’s Mushroom Home Grow Kits are now available for purchase in 30 Retail Stores Across Canada as well as on Happy Caps’ website and on Amazon.
The company expanded its point of sales of Happy Caps Home Grow Kits to over 70 retail stores across Canada including 13 Loblaws stores.
The company acquired SmartShop Utrecht and SmartShop Oss with plans to rebrand them to Wellness World. The stores will only carry Red Light Holland’s Magic truffles products.
Filament Health entered into a royalty-bearing, worldwide commercial licensing agreement with Psyence Biomedical for its natural psilocybin drug candidate, PEX010, specifically for use in palliative care. This agreement grants Psyence exclusive rights to commercialize PEX010 for the treatment of anxiety, depression and associated ailments within the context of palliative care in the UK, US, and EU. Under the terms of the deal, Filament is designated as the exclusive drug product supplier and is eligible to receive up to $3 million CAD in milestone payments linked to clinical development and marketing authorizations, alongside a low double-digit percentage royalty on future net sales.
Filament Health announced an agreement with The Centre for Addiction and Mental Health. Filament will supply CAMH with its natural psilocybin drug candidate for a proposed clinical trial studying the effects of psilocybin for treatment-resistant depression. The trial will be funded by the first ever Canadian federal grant to study psilocybin.
Filament Health announced that it had been issued 3 patents by the United States Patent and Trademark Office for the extraction and standardization of natural psilocybin and associated psychedelic compounds. The patents describe essential technology for transforming variable psychedelic raw materials into pharmaceutical-grade, standardized drug candidates.
Filament Health announced a licensing agreement with ATMA Journey Centers. Filament has licensed PEX010, a naturally extracted botanical drug candidate, to ATMA for use in clinical trials.
Filament Health entered into a licensing agreement with Cybin Therapeutics where Filament will license PEX010, its botanical psilocybin drug candidate, to CT for 2 upcoming Phase II clinical trials addressing depression and alcohol use disorder with an additional 2 planned for 2022.
Filament Health was included in Health Canada’s list of licensed psilocybin producers.
The company acquired MiniChamp which has specialized in home cultivation packages for mushrooms for almost 30 years. The company will gain access to MiniChamp’s production farm and mass distribution relationships to over 20 EU countries and over 100 retail shops to help with the launch of Mistercap Mushroom Home Grow Kits.
The company was the head sponsor of the Psy-Fi Festival in the Netherlands and the exclusive provider of natural psilocybin products at and also featured their technology Wisdom VR and Wisdom Truffle. The company also provided preparation and integration workshops to promote the responsible use of psychedelics.
The company partnered with Wiz Khalifa to launch a new psychedelics and mushrooms wellness brand called MISTERCAP. The brand will initially launch with a functional mushroom home grow kit and will expand to other legal, functional and innovative mushroom products, as well as a line of apparel and accessories, to be made available across the EU and North America. The companies are also committed to creating educational and responsible use messaging in relation to the use of any products made available by the brand. MISTERCAP products will be intended to help promote a healthy lifestyle.
The company acquired 100 acres of farmland where they plan on building a 65,000 sq ft in the township of Cavan-Monaghan in Peterborough, Ontario.
The company sponsored a groundbreaking group microdosing concert aimed to gather insights for the company in preparation for the legalization of psilocybin services in Oregon in accordance with Measure 109. The event will include a preparation session, a dosing session guided by experienced facilitators and an optional integration session. The event is organized by Sacred Journey Amsterdam and the New European Ensemble which will accompany the dosing session with a 3-hour live classical music concert experienced while lying down. The concert will be given by mezzo-soprano Helena van Heel together with the extraordinary New European Ensemble. The company expects that by obtaining the consent of facilitators and participants, they will be able to collect and analyze data on best practices for group microdosing services. The company plans to compile a report and make recommendations to the regulatory bodies in Oregon and Washington state to inform rule promulgation for microsoding regulations. Red Light Holland premium iMicrodose psilocybin truffles will be available for participants at the event.
The company was granted authorization for the first ever import of psilocybin from its iMicrodose Packs into St. Vincent and the Grenadines to be tested in preparation for further research by Caribbean Gold Standard Laboratory with the goal of prescribed medical patient use in the country.
The company signed an exclusive distribution deal with Conor McGregor’s sports recovery line TIDL Sport. SR Wholesale’s territory to distribute TIDL Sport will be the country of The Netherlands and on a case-by-case basis where no there is no conflict with an existing TIDL Sport Distributor, into all regions of Europe.
2023
Radix Motion was granted patent number: 11,806,16. Radix Motion’s allowed claims are directed to the use of human movement data in psychedelic-assisted therapy, including as a tool to promote positive experiences, to prevent negative experiences, to predict and personalize individual patient experiences, and to evaluate the efficacy of the therapy.
CCrest Laboratories finished 5 months stability tests for the microdosing capsules developed from psilocybin truffles grown in the company’s farm in The Netherlands, confirming stability of psilocybin and psilocin. The capsules are intended to be distributed in Australia and New Zealand by NUBU Pharmaceuticals.
Happy Caps Home Grow Mushroom Kits became available in over 110 retail stores in Canada including 36 Canadian Tire Stores.
Happy Caps Mushroom Farm signed a distribution deal with Longo Brothers Fruit Markets expanded the POS of Mushroom Home Grow Kits to over 135 stores across Canada including Longo’s 31 locations in southern Ontario.
The company launched custom Mistercap apparel at Misteracap’s website and at the Wiz Khalifa High School Reunion Concert in Toronto. The MISTERCAP brand, in conjunction with Red Light Holland, is also committed to creating educational and responsible use messaging in relation to the use of any products made available by the brand.
The company announced that AEM New Brunswick Shiitake Mushrooms are available in over 100 locations Eastern Canada, including Loblaws owned retailers in Ottawa; Costco locations in both Ottawa and Gatineau; all Loblaws and Your Independent Grocer supermarkets in Ottawa and Whole Foods Markets in Ottawa, also including all 47 Farm Boy Stores in Ontario, Canada.
The company announced a distribution agreement with New Zealand-based NUBU Pharmaceuticals with distribution ties to Australia, to explore the possibility of legal import and distribution of Red Light Holland’s psilocybin microdosing capsules to Australasia.
Health Canada approved the importation of 3 KG of the company’s natural psilocybin truffles grown in the Netherlands to Red Light’s partner CCrest Laboratories in Montreal, Canada for the purposes of product development of homogenized powder for microdosing capsules.
Ccrest Laboratories finalized tests required for a full certificate of analysis of the capsules developed from Red Light Hollands psilocybin truffles grown in their farm in The Netherlands and imported to Canada under a Health Canada approved psilocybin import license. These final tests have confirmed there are no pesticides or heavy metals in the capsules and that they are free from bio-contaminants meeting the requirements needed by NUBU Pharmaceuticals for furthering the goal of distribution in Australasia.
Filament Health announced a 2nd supply agreement with The Centre For Addiction And Mental Health to supply them with the company’s botanical psilocybin drug candidate, PEX010. CAMH will study the effects of psilocybin for the treatment of amnestic mild cognitive impairment in a Health Canada-approved clinical trial.
Filament Health formed a JV called Magdalena Biosciences with Jaguar Health and One Small Planet to develop novel, natural prescription medicines derived from plants for mental health indications including ADHD in adults. 1 million in funding is given by One Small Planet in quarterly increments based on milestones achieved by Magdalena Biosciences. Magdalena Biosciences will leverage Jaguar’s proprietary medicinal plant library and Filament’s proprietary drug development technology and the goal of the collaboration is to extend the botanical drug development capabilities of Jaguar and Filament to develop pharmaceutical-grade, standardized drug candidates for mental health disorders, and to partner with a potential future licensee to develop and commercialize these novel plant-based drugs. Later in the year, Magdalena Biosciences completed an import of coca leaf from the Empresa Nacional de la Coca in Peru to Filament’s Metro Vancouver research and development facility to be used for initial research purposes, looking at neuropsychiatric indications.
Filament Health announced an exclusive global licensing agreement with NeoLumina Bioscience where Filament will license its proprietary botanical psilocybin drug candidate, PEX010, and associated intellectual property, to NeoLumina for clinical and commercial development related to eating disorders.
Filament Health announced that it will supply psilocybin for two clinical trials which have received The Canadian Institutes of Health Research Operating Grants for Psilocybin-assisted Psychotherapy for Mental Health and Substance Use Disorders. The clinical trials will study the effects of Filament’s botanical psilocybin drug candidate, PEX010, for alcohol use disorder and treatment resistant depression.
Filament Health announced the completion of the first-ever Nagoya Protocol-compliant import of Tabernanthe iboga root from Gabon to Filament’s Metro Vancouver research and development facility. The iboga root will undergo analysis at Filament’s facility, and be transformed into total alkaloid iboga extract, in partnership with Terragnosis, a company dedicated to producing ethically sourced and high quality ibogaine and iboga extracts.
Filament Health and PharmAla Biotech announced the GMP release of MDMA capsules at the Metro Vancouver facility operated by Filament’s subsidiary Psilo Scientific.
Filament Health entered into a licensing agreement with Reset Pharmaceuticals where Filament will license its proprietary botanical psilocybin drug candidate, PEX010, and associated intellectual property, to Reset Pharma for a phase 2 clinical trial for the treatment of demoralization syndrome.
2024
The company secured a national partnership with Costco Canada to launch an exclusive “Mega Block” 2kg home grow kit to be available at the majority of Costco locations across Canada, approximately 100 locations receiving 20,000 units. Following the successful launch of the Happy Caps Mega Block 2kg mushroom home grow kits at Costco in Canada, Happy Caps received an informal projection letter from Costco Canada indicating a prospective reorder of nearly double the initial quantity, suggesting a future order of 40,000 kits. The next order was shown to be 26,880 units, a 33% increase from the initial order of 20,160 units and an additional order came with 6,720 units after that with expanded distribution to 82 Costco locations across Canada.
Filament Health has completed shipments of PEX010 to Johns Hopkins University for a clinical trial studying cannabis use disorder and to Dana-Farber Cancer Institute for a trial studying the treatment of pain in cancer patients. In Belgium, Filament has supplied PEX010 to Ghent University which will examine its effects for the treatment of anxiety and mood disorder, and to Brugmann University Hospital which will study PEX010 for alcohol use disorder. In Canada, University Health Network plans to begin a Phase II clinical trial studying PEX010 for treatment-resistant depression, and the University of Calgary will study PEX010 for alcohol use disorder. In Israel, Jerusalem Center for Mental Health will investigate Filament’s drug candidate for depression and anxiety in terminal illnesses.
Filament Health announced that the FDA accepted its IND-application for PEX010, its botanical psilocybin drug candidate, for the treatment of SUD.
The commercial licensing agreement between Filament Health and Psyence Biomed was terminated by both parties.
MISTERCAP’S mushroom home grow kits were selected by Urban Outfitters for nationwide retail distribution in the US as well as online sales.
The company announced that Happy Caps products are now available in over 270 retail stores across Canada.
The company announced it has entered into a 1-year consulting relationship with PharmAla Biotech Holdings to consult on the development of clinical-grade psilocybin drug product extracted from Red Light Holland’s naturally occurring psilocybin truffles. The agreement included the provision that upon completion of the drug product to specification, PharmAla and Red Light may enter into a sales agreement, where PharmAla would sell the products or provide them to its affiliates in global markets as Red Light’s exclusive sales agent.
The company announced that it had initiated an experimental research project with Pharmala and their researchers to develop a process for the commercial manufacture of natural-source API derived from the company’s psilocybin truffles.
The company launched SR Wholesale North America, its fresh mushroom sales division.
The company partnered with Professor David Nutt and Drug Science to analyze iMicroapp data.
Acadian Exotic Mushrooms partnered with Agro Projects for the construction of AEM Farms Ontario, an 85,000 sq ft state-of-the-art vertical mushroom farm and composting facility in Peterborough, Ontario.
The company entered into an amended and restated IP licensing agreement, removing all guaranteed payments payable to MISTERCAP’S including monthly marketing fees, meaning the sole form of payment to MISTERCAP’S will be royalty payments of 15% for all sales under the MISTERCAP’S brand except for sales that originate from the MISTERCAP’S website which are subject to a 20% royalty fee. The IP agreement was extended to a term of 5 years and the company is to pay MISTERCAP’S a one-time catch-up payment in the amount of US$175,000 owed by the company.
The company announced the successful completion of a comprehensive extraction protocol, with associated report by PharmAla Biotech.
The company’s partnership with Pharmala ended on the 3rd of September.
The company launched FarmCare Health, an initiative designed to integrate farm-fresh food, specifically functional mushrooms, into the healthcare system as a form of food as medicine.
Happy Caps partnered with Oregon-based Trailbridge Mushroom Farms to scale the production and distribution of its gourmet mushroom home grow kits of Shiitake, Lion’s Mane and Oyster across the US West Coast. Under the agreement, Happy Caps provided an automated bagging machine to Trailbridge Farms to enhance co-packaging capacity.
The company entered into a strategic partnership with Irvine Labs to manufacture its 0.5 mg psilocybin microdosing capsules in a pharmaceutical-grade, cGMP-compliant environment.
2025
Happy Caps received a Natural Product Number (NPN) from Health Canada for its sugar-free Functional Daily mushroom gummies featuring Shiitake and Lion’s Mane, the product was recognized for its antioxidant properties and immunomodulating potential.
Happy Caps confirmed a re-stocking of 20,160 units of its 2 KG Mega Block of Shiitake, Lion’s Mane and Oyster in varieties at Costco nationwide across Canada.
Happy Caps started selling its mushroom home grow kits of Shiitake, Lion’s Mane, and Oyster in 66 Safeway stores across Oregon and Washington. Each store received 36 kits as well as branded floor displays. This pushed the brand’s seasonal retail footprint to over 430 stores across North America.
The company partnered with Arizona State University to support Dr. Candace Lewis’s “Psychedelic Genome Project,” which investigates how psilocybin influences gene expression and the epigenome. Through this collaboration, Red Light Holland leveraged its Netherlands-based infrastructure and customer network to facilitate the study by handling participant recruitment, distributing saliva collection kits, and providing ongoing administrative and logistical support. The initiative aimed to identify biological markers of psilocybin response, ultimately seeking to advance the development of personalized, evidence-based psychedelic therapies.
The company launched a Bitcoin balance sheet strategy to diversify its treasury, allowing the allocation of up to C$2 million for Bitcoin and related assets. The company had then bought 210,000 CAD worth and had invested a total of 472,760 CAD within 2 months later.
Happy Caps announced an expansion of its partnership selling growkits at Safeway, now selling at 123 Safeway stores, an 86% increase from the 66 original and covers 2 seasonal sales programs, late fall and the 2025 holiday season with 4,428 growkits.
The company received an official Certificate of Analysis (COA) for its naturally derived psilocybin truffles via its partner, Irvine Labs.
Irvine Labs received a second United States Controlled Substances import permit from the DEA, allowing for the importation of up to 5 KG of psilocybin truffles from the company’s Netherlands facility. This followed by the company transporting 5 KG to Irvine Labs.
2026
The company entered into a definitive agreement to acquire Filament Health in an all-share transaction. The transaction will give the company 76 issued patents, the flagship botanical psilocybin drug candidate PEX010 and a Health Canada Level 8 Dealer’s Licence and GMP-compliant manufacturing facilities. Red Light Holland shareholders kept around a 70% ownership of the combined company.
The company announced a strategic engagement with Kala Bio to utilize their Researgency.ai platform to support the clinical development of PEX010, a patented botanical psilocybin drug candidate originating from Filament Health.
The company announced its support of the University of California, San Francisco Carhart-Harris Lab’s Global Psychedelic Study by directing clinical researchers and participants using the PEX010 psilocybin drug candidate to the study.
The company reported that its subsidiary Filament Health expanded its clinical network in March 2026 by signing 3 new license agreements for PEX010 research at the University of Melbourne, Imperial College London and the University of Calgary. Additionally, the company completed 2 research shipments of PEX010 to Queen’s University and the Centre for Addiction and Mental Health to support ongoing clinical trials in oncology and treatment-resistant depression.
The company highlighted a new Phase 1 clinical study published in Frontiers in Public Health, conducted by the University of Washington, which demonstrated the efficacy of multi-session psilocybin therapy. Using Filament Health’s PEX010 botanical drug candidate, the study found that a second, higher-dose psilocybin session provided meaningful and sustained improvements in anxiety and depression for metastatic cancer patients who had only partially responded to an initial treatment. After the second session, 69% of participants fell below clinical thresholds for anxiety and depression, with benefits lasting up to 24 weeks and no serious adverse events reported.
The company announced the continued expansion of its clinical supply chain by delivering repeat shipments of PEX010 to the University of Calgary for studies on alcohol use disorder and post-concussion symptoms. Additionally, the company scheduled new, first-time shipments of PEX010 to the University of British Columbia and the University of Calgary for upcoming trials investigating bipolar II disorder and the role of cortisol in psilocybin-assisted therapy.
The company acquired Filament Health.
Filament Health expanded the distribution of its patented PEX010 botanical psilocybin drug candidate with several new shipments across North America. These include repeat shipments to the University of Calgary for clinical studies on alcohol use disorder and persistent post-concussion symptoms, a second shipment to UCSF for a chronic low back pain trial, and a first-time shipment to a new Canadian academic institution. Additionally, the company delivered multiple shipments to support patients in approved compassionate use programs, reflecting growing real-world therapeutic demand, as well as a shipment to a third-party analytical laboratory to ensure ongoing GMP compliance and quality control across its supply chain.
The company highlighted a peer-reviewed study published in JAMA Network Open, which found that a single dose of psilocybin significantly reduced cocaine use in adults with cocaine use disorder over a six-month period, with a meaningful subset achieving complete abstinence. Notably, Red Light’s subsidiary, Filament Health, holds the exclusive worldwide license to this trial’s data and associated intellectual property, which the company intends to use to accelerate the development of its own patented botanical psilocybin drug candidate, PEX010. As Filament has already secured Phase 2 clinical trial authorization for PEX010 in stimulant use disorder from both the FDA and Health Canada, these findings provide a critical regulatory foundation to advance PEX010 as a potential therapeutic option for this chronic condition, for which there are currently no FDA-approved pharmacotherapies.
The company expanded the clinical reach of its PEX010 botanical psilocybin drug candidate with several new research shipments to Canadian academic institutions. These include ongoing support for the Bruyère Health Research Institute’s upcoming Phase 3 trial investigating microdose psilocybin for psychological distress in palliative care patients, a first-time shipment to the University of Calgary for a study exploring the mechanistic role of the subjective psychedelic experience in healthy adults, and the confirmation that a previously announced shipment is supporting a landmark University of British Columbia study on psilocybin-assisted therapy for treatment-resistant depression in Bipolar II disorder.
The company expanded its partnership with Allu Therapeutics in New Zealand by adding its subsidiary Filament Health as a supplying affiliate. This agreement introduces a GMP-compliant, standardized microdose format of Filament’s patented botanical psilocybin drug candidate, PEX010, which the company believes to be the first of its kind globally. By providing this pharmaceutical-grade product, the partnership aims to support New Zealand’s evolving regulatory framework, which allows authorized psychiatrists to prescribe psilocybin to treatment-resistant patients on a case-by-case basis.
Filament Health will supply its standardized, patented botanical psilocybin drug candidate, PEX010, to the University of California, San Francisco for a new independently sponsored clinical trial. This double-blind, randomized study will investigate the safety, feasibility, and potential mechanisms of psilocybin in healthy older adults who report low well-being, specifically focusing on how the compound may influence neuroinflammatory markers, brain electrical activity (EEG), and structural/functional brain changes (MRI) associated with preclinical Alzheimer’s disease. By utilizing PEX010, the study aims to determine if a single dose of psilocybin can modulate markers of neuroinflammation, which is increasingly recognized as a key factor in mood, cognition, and neurodegenerative processes. This agreement marks the selection of PEX010 for more than 80 global research studies.
Filament Health signed an agreement to supply its PEX010 botanical psilocybin drug candidate to the GHU Paris Psychiatrie & Neurosciences in France. The PEX010 supply will support the “KETAPSYCHECOG” study, a randomized, double-blind, cross-over clinical trial in healthy volunteers designed to compare the behavioral and neural effects of psilocybin versus ketamine.
The company announced positive preclinical study results from Magdalena Biosciences, a joint venture held through its subsidiary, Filament Health which demonstrates that a novel coca leaf extract successfully prevented weight gain in mice on a high-fat diet without altering food intake or physical activity. This extract is being developed as a prescription drug candidate for post-GLP-1 weight loss management, aiming to address the common challenge of weight regain after patients discontinue GLP-1 medications. Conducted in collaboration with the University of Calgary, the study utilized coca leaf provided by Peru’s state-run ENACO under international compliance standards. Red Light Holland plans to support the continued development of this candidate under the U.S. Food and Drug Administration’s Botanical Guidance.
Filament Health entered into an agreement with the ARQ National Psychotrauma Centre in the Netherlands to supply its patented PEX010 botanical psilocybin drug candidate for a new pilot feasibility study. The research will investigate the use of psilocybin-assisted psychotherapy to treat post-traumatic stress disorder in military veterans, a population for whom conventional treatments are often insufficient.
The company started its largest-ever production run of its patented botanical psilocybin drug candidate, PEX010, in response to sustained global demand from academic and clinical research institutions. A key highlight of this expansion is the introduction of a new 0.5 mg dose, which complements the existing 1 mg, 5 mg and 25 mg strengths. This establishes PEX010 as having the widest standardized dosing range available for a natural psilocybin candidate, spanning from sub-hallucinogenic microdoses to full therapeutic levels.